The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Open accessAbstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these compounds bind selectively to their respective receptors in rodents, they have now been shown to exhibit relatively high affinities for both OXTR and AVPR1a in primates (27,28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“For example, studies employing recombinant expression systems to examine selectivity of human, rat, and mouse OT and AVP receptors have shown that only the human OTR is selective for OT using a standard criterion [34; 35] (Table 1).”
From Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery (2018) · cites this paper as [35]
In the citing paper
“The limited information on the distributions of OTR and V1aR in primate neural tissue is due in part to the lower selectivity for radioligands targeting OTR (125I-OVTA) and V1aR (125I-LVA) autoradiography, relative to high selectivity of radioligands for these receptors in rodents, as well as the promiscuous binding profile of both radioligands for OTR and V1aR (Freeman et al., 2014a, 2014b; Man”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Manning et al., 2012
In the citing paper
“There was also no difference in AVP levels, suggesting no peripheral cross-reactivity, which is more likely to occur with higher levels of oxytocin exposure.71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,825
Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction
Berridge, M. J., & Irvine, R. F. (1984) · Nature · doi:10.1038/312315a0 · Cited by 6,086
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,135
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Stewart, J. M. (1976) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337608068099 · Cited by 1,770
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martínez, J., & Khrestchatisky, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,523
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Research works printed but not linked: 13
- Manning M, 1981, The Pituitary, 265
- Manning M, 1985, Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, 131
- Manning M, 1991, Vasopressin, 297
- Manning M, 2005, Peptides 2004, 101
- Lebl M, 1988, Handbook of Neurohypophyseal Hormone Analogs, 17
- Jard S, 1998, Adv Exp Med Biol, 1
- 10.1210/en.137.9.3906 · DOI
- Wisniewski K, 2010, Peptides 2010, 306
- Manning M, 2010, Peptides 2010, 366
- Guillon G, 2007, Peptides 2006, 742
- 10.1021/jm010526 · DOI
- Mimoun MB, 2001, Peptides 2000, 589
- Reichert J, 2010, Development Trends for Peptide Therapeutics
Cited by
Sorted by citations
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 2,074
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,150
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 561
Dumais, K. M., & Veenema, A. H. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.04.003 · Cited by 520
“However, this study used [3H] OT and, like [3H] VP, [3H] OT may not exclusively bind OTR (Mouillac et al., 1995; Manning et al., 2012), and thus possibly may mask potential sex differences in OTR binding.”
MethodNeuromodulation by Oxytocin and Vasopressin
Stoop, R. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.025 · Cited by 506
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 454
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16177 · Cited by 393
Self-citationRilling, J. K., DeMarco, A. C., Hackett, P. D., Chen, X., Gautam, P., Stair, S., Haroon, E., Thompson, R., Ditzen, B., Patel, R., et al. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.09.022 · Cited by 343
“For example, if central AVP levels are higher in men, additional exogenous AVP could saturate AVP receptors and cross-react with OT receptors (Manning et al., 2012; Young and Flanagan-Cato, 2012) and this, in turn, could drive increases in activity in regions involved in reward and bonding.”
BackgroundAssembling the puzzle: pathways of oxytocin signaling in the brain
Grinevich, V., Knobloch-Bollmann, H. S., Eliava, M., Busnelli, M., & Chini, B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.013 · Cited by 309
Self-citationOxytocin: Its Mechanism of Action and Receptor Signalling in the Myometrium
Arrowsmith, S., & Wray, S. (2014) · Journal of Neuroendocrinology · doi:10.1111/jne.12154 · Cited by 308
Insular cortex mediates approach and avoidance responses to social affective stimuli
Rogers-Carter, M. M., Varela, J. A., Gribbons, K. B., Pierce, A. F., McGoey, M. T., Ritchey, M., & Christianson, J. P. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0071-y · Cited by 277
Song, Z., & Albers, H. E. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.10.004 · Cited by 244
Oxytocin and vasopressin: powerful regulators of social behavior
Caldwell, H. K. (2017) · The Neuroscientist · doi:10.1177/1073858417708284 · Cited by 216
Amygdala, neuropeptides, and chronic pain-related affective behaviors
Neugebauer, V., Mazzitelli, M., Cragg, B., Ji, G., Navratilova, E., & Porreca, F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108052 · Cited by 220
An Allostatic Theory of Oxytocin
Quintana, D. S., & Guastella, A. J. (2020) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2020.03.008 · Cited by 223
Freeman, S. M., & Young, L. J. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12382 · Cited by 196
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
BackgroundPaloyelis, Y., Doyle, O. M., Zelaya, F. O., Maltezos, S., Williams, S. C., Fotopoulou, A., & Howard, M. A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.005 · Cited by 187
Albers, H. E. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.07.001 · Cited by 200
Freeman, S. M., Inoue, K., Smith, A. L., Goodman, M. M., & Young, L. J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.023 · Cited by 185
“Although the behavioral effects of OTare widely assumed to mediated by central OXTR, OT does cross react with the AVP receptors and vice versa (Manning et al., 2012), and some of the behavioral effects of OT are mediated by AVPR1A (Schorscher-Petcu et al.”
BackgroundMacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Molecular Basis of Oxytocin Receptor Signalling in the Brain: What We Know and What We Need to Know
Busnelli, M., & Chini, B. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_6 · Cited by 168
Self-citationPeris, J., MacFadyen, K. A., Smith, J. A., de Kloet, A. D., Wang, L. A., & Krause, E. G. (2016) · The Journal of Comparative Neurology · doi:10.1002/cne.24116 · Cited by 158
Freeman, S. M., Walum, H., Inoue, K., Smith, A. L., Goodman, M. M., Bales, K. L., & Young, L. J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.055 · Cited by 153
The role of oxytocin in male and female reproductive behavior
Veening, J. G., A, T. R. D. J., Waldinger, M. D., Korte, S. M., & Olivier, B. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.045 · Cited by 156
Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design
Koehbach, J., O’Brien, M., Muttenthaler, M., Miazzo, M., Akcan, M., Elliott, A. G., Daly, N. L., Harvey, P. J., Arrowsmith, S., Gunasekera, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311183110 · Cited by 155
The action radius of oxytocin release in the mammalian CNS: from single vesicles to behavior
Chini, B., Verhage, M., & Grinevich, V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.005 · Cited by 141
Self-citationQuintana, D. S., Alvares, G. A., Hickie, I. B., & Guastella, A. J. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.011 · Cited by 149
Miller, J. L., Tamura, R., Butler, M. G., Kimonis, V. E., Sulsona, C. R., Gold, J., & Driscoll, D. J. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38160 · Cited by 149
Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain
de Araujo, A. D., Mobli, M., Castro, J., Harrington, A. M., Vetter, I., Dekan, Z., Muttenthaler, M., Wan, J., Lewis, R. J., King, G. F., et al. (2014) · Nature Communications · doi:10.1038/ncomms4165 · Cited by 142
A genetically encoded sensor measures temporal oxytocin release from different neuronal compartments
Qian, T., Wang, H., Wang, P., Geng, L., Mei, L., Osakada, T., Wang, L. A., Tang, Y., Kania, A., Grinevich, V., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01561-2 · Cited by 147
Blevins, J. E., & Baskin, D. G. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.05.023 · Cited by 135
Peptides, Antibodies, Peptide Antibodies and More
Trier, N. H., Hansen, P. B., & Houen, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246289 · Cited by 132
Oxytocin, vasopressin, and the motivational forces that drive social behaviors
Caldwell, H. K., & Albers, H. E. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_390 · Cited by 129
Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., & McGregor, I. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.125 · Cited by 128
Oliveira, V. E. D. M., Lukas, M., Wolf, H. N., Durante, E., Lorenz, A., Mayer, A.-L., Bludau, A., Bosch, O. J., Grinevich, V., Egger, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23064-5 · Cited by 126
Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors
Sridharan, R., Zuber, J., Connelly, S. M., Mathew, E., & Dumont, M. E. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.09.005 · Cited by 133
Rault, J., van den Munkhof, M. H., & Buisman‐Pijlman, F. T. A. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01521 · Cited by 122
Oxytocin administration enhances controlled social cognition in patients with schizophrenia
Woolley, J. D., Chuang, B., Lam, O., Lai, W., O’Donovan, A., Rankin, K. P., Mathalon, D. H., & Vinogradov, S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.024 · Cited by 116
Song, Z., McCann, K. E., McNeill, J. K., Larkin, T. E., Huhman, K. L., & Albers, H. E. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.08.005 · Cited by 111
Physiology of invertebrate oxytocin and vasopressin neuropeptides
Gruber, C. W. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2013.072561 · Cited by 110
Review cyclic peptides on a merry‐go‐round; towards drug design
Tapeinou, A., Matsoukas, M., Simal, C., & Tselios, T. V. (2015) · Biopolymers · doi:10.1002/bip.22669 · Cited by 111
Kovac, S., & Walker, M. C. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.015 · Cited by 116
Quintana, D. S., Westlye, L. T., Hope, S., Nærland, T., Elvsåshagen, T., Dørum, E., Rustan, Ø., Valstad, M., Rezvaya, L., Lishaugen, H., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.103 · Cited by 111
A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
Feifel, D., Shilling, P. D., & MacDonald, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.025 · Cited by 110
Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors
Busnelli, M., Bulgheroni, E., Manning, M., Kleinau, G., & Chini, B. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.202994 · Cited by 102
Self-citationSong, Z., Borland, J. M., Larkin, T. E., O’Malley, M., & Albers, H. E. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.09.001 · Cited by 101
Tunstall, B. J., Kirson, D., Zallar, L. J., McConnell, S. A., Vendruscolo, J. C. M., Ho, C. P., Oleata, C. S., Khom, S., Manning, M., Lee, M. R., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.2006421 · Cited by 104
Self-citationA brief history of oxytocin and its role in modulating psychostimulant effects
Carson, D. S., Guastella, A. J., Taylor, E. R., & McGregor, I. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473788 · Cited by 105
Sabihi, S., Dong, S. M., Durosko, N. E., & Leuner, B. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00258 · Cited by 101
Noble, E. E., Billington, C. J., Kotz, C. M., & Wang, C. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00118.2014 · Cited by 102
Estrogen Permits Vasopressin Signaling in Preoptic Kisspeptin Neurons in the Female Mouse
Piet, R., Fraissenon, A., Boehm, U., & Herbison, A. E. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4587-14.2015 · Cited by 94
The application of sulfur-containing peptides in drug discovery
Zhao, J., & Jiang, X. (2018) · Chinese Chemical Letters · doi:10.1016/j.cclet.2018.05.026 · Cited by 97
The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis
Lawson, E. A., Olszewski, P. K., Weller, A., & Blevins, J. E. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12805 · Cited by 100
Han, R. T., Kim, Y., Park, E. H., Kim, J. Y., Ryu, C., Kim, H. Y., Lee, J., Pahk, K., Cui, S., Kim, H., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00246 · Cited by 92
Antiaggressive activity of central oxytocin in male rats
Calcagnoli, F., de Boer, S. F., Althaus, M., den Boer, J. A., & Koolhaas, J. M. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3124-7 · Cited by 90
Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward
Bradley, E., & Woolley, J. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.007 · Cited by 92
Vasopressin and Oxytocin in Control of the Cardiovascular System
Japundžić‐Žigon, N. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311020008 · Cited by 89
Rocchetti, M., Radua, J., Paloyelis, Y., Xenaki, L., Frascarelli, M., Caverzasi, E., Politi, P., & Fusar‐Poli, P. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12185 · Cited by 83
Potential of Oxytocin in the Treatment of Schizophrenia
Shilling, P. D., & Feifel, D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0315-x · Cited by 84
Rebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction
Bowen, M. T., & Neumann, I. D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.003 · Cited by 87
Targetable cellular signaling events mediate vascular pathology in vascular Ehlers-Danlos syndrome
Bowen, C. J., Calderón, J. F., Burger, Z., Rykiel, G., Davis, E. C., Helmers, M. R., Benke, K. S., MacFarlane, E. G., & Dietz, H. C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130730 · Cited by 81
Sabihi, S., Dong, S. M., Maurer, S., Goodpaster, C. M., & Leuner, B. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.024 · Cited by 87
Kubo, A., Shinoda, M., Katagiri, A., Takeda, M., Suzuki, T., Asaka, J., Yeomans, D. C., & Iwata, K. (2017) · Pain · doi:10.1097/j.pain.0000000000000808 · Cited by 79
Muttenthaler, M., Andersson, Å., Vetter, I., Menon, R., Busnelli, M., Ragnarsson, L. K. N., Bergmayr, C., Arrowsmith, S., Deuis, J. R., Chiu, H. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan3398 · Cited by 78
Distribution of oxytocin and co-localization with arginine vasopressin in the brain of mice
Otero‐García, M., Agustín‐Pavón, C., Lanuza, E., & Martínez‐Garciá, F. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1111-y · Cited by 80
Hicks, C., Ramos, L., Reekie, T., Misagh, G. H., Narlawar, R., Kassiou, M., & McGregor, I. S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12613 · Cited by 76
Passoni, I. P., Leonzino, M., Gigliucci, V., Chini, B., & Busnelli, M. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12363 · Cited by 76
Self-citationHo, J. M., Anekonda, V. T., Thompson, B. W., Zhu, M., Curry, R. W., Hwang, B. H., Morton, G. J., Schwartz, M. W., Baskin, D. G., Appleyard, S. M., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1148 · Cited by 74
Steinman, M. Q., Laredo, S. A., Lopez, E. M., Manning, C. E., Hao, R. C., Doig, I. E., Campi, K. L., Flowers, A. E., Knight, J. K., & Trainor, B. C. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.009 · Cited by 73
Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., & Devi, L. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15481 · Cited by 72
Dumais, K. M., Alonso, A. G., Immormino, M. A., Bredewold, R., & Veenema, A. H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.007 · Cited by 79
Oxytocin and vasopressin enhance responsiveness to infant stimuli in adult marmosets
Taylor, J. H., & French, J. A. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.10.002 · Cited by 68
Busnelli, M., Kleinau, G., Muttenthaler, M., Stoev, S., Manning, M., Bibic, L., Howell, L. A., McCormick, P. J., Di Lascio, S., Braida, D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00564 · Cited by 67
Self-citationNeuropeptide diversity and the regulation of social behavior in New World primates
French, J. A., Taylor, J. H., Mustoe, A. C., & Cavanaugh, J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.03.004 · Cited by 66
Oxytocin modulates fMRI responses to facial expression in macaques
Liu, N., Hadj-Bouziane, F., Jones, K. B., Turchi, J. N., Averbeck, B. B., & Ungerleider, L. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508097112 · Cited by 65
Habashi, J. P., MacFarlane, E. G., Bagirzadeh, R., Bowen, C. J., Huso, N. D., Chen, Y., Bedja, D., Creamer, T. J., Rykiel, G., Manning, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat4822 · Cited by 67
Self-citationSomato‐dendritic vasopressin and oxytocin secretion in endocrine and autonomic regulation
Brown, C. H., Ludwig, M., Tasker, J. G., & Stern, J. E. (2020) · Journal of Neuroendocrinology · doi:10.1111/jne.12856 · Cited by 72
Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Goodin, B. R., Ness, T. J., & Robbins, M. T. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666141027111843 · Cited by 66
Activation of Supraoptic Oxytocin Neurons by Secretin Facilitates Social Recognition
Takayanagi, Y., Yoshida, M., Takashima, A., Takanami, K., Yoshida, S., Nishimori, K., Nishijima, I., Sakamoto, H., Yamagata, T., & Onaka, T. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.021 · Cited by 69
Jiang, Y., & Platt, M. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-25607-1 · Cited by 69
Targeting the Oxytocin System: New Pharmacotherapeutic Approaches
Gulliver, D. W., Werry, E. L., Reekie, T. A., Katte, T. A., Jorgensen, W. T., & Kassiou, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.11.001 · Cited by 67
Song, T.-J., Lan, X.-Y., Wei, M., Zhai, F.-J., Boeckers, T. M., Wang, J., Yuan, S., Jin, M.-Y., Xie, Y., Dang, W.-W., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00111 · Cited by 67
Reyes, A. G., Ménaouar, A., Yip, D., Danalache, B. A., Plante, É., Noiseux, N., Gutkowska, J., & Jankowski, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.04.028 · Cited by 63
Preclinical Toxicity Screening of Intrathecal Oxytocin in Rats and Dogs
Yaksh, T. L., Hobo, S., Peters, C. M., Osborn, K. G., Richter, P. J., Rossi, S. S., Grafe, M. R., & Eisenach, J. C. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000148 · Cited by 63
Sparapani, S., Millet-Boureima, C., Oliver, J., Mu, K., Hadavi, P., Kalostian, T., Ali, N., Avelar, C. M., Bardies, M., Barrow, B., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010089 · Cited by 64
Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides
Glavaš, M., Gitlin‐Domagalska, A., Dębowski, D., Ptaszyńska, N., Łęgowska, A., & Rolka, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063068 · Cited by 63
Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate
Anand, U., Bandyopadhyay, A., Jha, N. K., de la Lastra, J. M. P., & Dey, A. (2022) · BioFactors · doi:10.1002/biof.1913 · Cited by 68
Spoljaric, A., Seja, P., Spoljaric, I., Virtanen, M. A., Lindfors, J., Uvarov, P., Summanen, M., Crow, A., Hsueh, B., Puskarjov, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717337114 · Cited by 60
Janeček, M., & Dabrowska, J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2889-8 · Cited by 63
Insights into the molecular evolution of oxytocin receptor ligand binding
Koehbach, J., Stockner, T., Bergmayr, C., Muttenthaler, M., & Gruber, C. W. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120256 · Cited by 61
Modulation of social behavior by distinct vasopressin sources
Rigney, N., Vries, G. J. D., & Petrulis, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127792 · Cited by 64
Ferris, C. F., Yee, J. R., Kenkel, W. M., Dumais, K. M., Moore, K., Veenema, A. H., Kulkarni, P. P., Perkybile, A. M., & Carter, C. S. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00245 · Cited by 60
Neuropeptide S Activates Paraventricular Oxytocin Neurons to Induce Anxiolysis
Grund, T., Goyon, S., Li, Y., Eliava, M., Liu, H., Charlet, A., Grinevich, V., & Neumann, I. D. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2161-17.2017 · Cited by 61
Kohli, S., King, M. V., Williams, S. A., Edwards, A., Ballard, T. M., Steward, L. J., Alberati, D., & Fone, K. C. F. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0171-0 · Cited by 61
Smith, C. J. W., DiBenedictis, B. T., & Veenema, A. H. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.02.001 · Cited by 59
Do marmosets care to share? Oxytocin treatment reduces prosocial behavior toward strangers
Mustoe, A. C., Cavanaugh, J., Harnisch, A. M., Thompson, B. E., & French, J. A. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.04.015 · Cited by 59
The oxytocin receptor signalling system and breast cancer: a critical review
Liu, H., Gruber, C. W., Alewood, P. F., Möller, A., & Muttenthaler, M. (2020) · Oncogene · doi:10.1038/s41388-020-01415-8 · Cited by 60
Oxytocin and vasopressin modulate the social response to threat: a preclinical study
Bowen, M. T., & McGregor, I. S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000388 · Cited by 63
Loison, S., Cottet, M., Orcel, H., Adihou, H., Rahmeh, R., Lamarque, L., Trinquet, E., Kellenberger, E., Hibert, M., Durroux, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3006146 · Cited by 55
Self-citationSex Differences in the Embryonic Development of the Central Oxytocin System in Mice
Tamborski, S., Mintz, E. M., & Caldwell, H. K. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12364 · Cited by 55
Metadata
- Authors
- Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G.
- Affiliations
- University of Toledo (US)
- University of Warsaw (PL)
- Lodz University of Technology (PL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Manning, M.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2012-03-26
- Volume
- 24
- Issue
- 4
- Pages
- 609-628
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- PMC
- PMC3490377
- OpenAlex
- W1803779312
- Cited by
- 423
- References
- 244
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 22 · 2023: 25 · 2022: 32 · 2021: 36 · 2020: 31 · 2019: 40 · 2018: 34 · 2017: 35 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 30 · 2012: 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Centre National de la Recherche Scientifique
- National Institute of General Medical Sciences (GM25280, R01GM025280)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- oxytocin, vasopressin, vasopressin receptor, oxytocin receptor, V1a receptor, V1b receptor, V2 receptor, peptide agonists, peptide antagonists, conivaptan, tolvaptan, fluorescent ligands, receptor localization, receptor dimerization, oxytocin analogues, receptor selectivity, species differences
- MeSH terms
- Animals, Arginine Vasopressin, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Oxytocin, Structure-Activity Relationship, Receptors, Vasopressin, Receptors, Oxytocin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
